Adage Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Adage Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$223K	Buy	10,000 +844	+9%	+$20.2K	﹤0.01%	911
2025 Q4	$245K	Sell	9,156 -2,475,000	-100%	-$59.1M	﹤0.01%	877
2025 Q3	$53M	Buy	2,484,156 +1,880,356	+311%	+$44.5M	0.08%	228
2025 Q2	$13M	Buy	+603,800	New	+$11.2M	0.02%	558
2023 Q3	–	Sell	-3,553,093	Closed	-$85.1M	–	863
2023 Q2	$85.1M	Buy	3,553,093 +2,328,093	+190%	+$51.7M	0.18%	132
2023 Q1	$23.1M	Buy	+1,225,000	New	+$23.3M	0.05%	379
2021 Q1	–	Sell	-80,000	Closed	-$4.28M	–	953
2020 Q4	$4.28M	Buy	+80,000	New	+$3.97M	0.01%	703
2016 Q2	–	Sell	-259,800	Closed	-$7.26M	–	681
2016 Q1	$7.26M	Buy	+259,800	New	+$5.66M	0.02%	567

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners's ACAD Position: Q1 2026 in Review

Adage Capital Partners increased its Acadia Pharmaceuticals (ACAD) stake by 9.2% in Q1 2026, buying an estimated $20.2K and bringing the position to 10,000 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #911.

Adage Capital Partners first reported a position in ACAD in Q1 2016 and has held it in 8 quarters since. The position peaked at $85.1M in Q2 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Adage Capital Partners held 10,000 shares of Acadia Pharmaceuticals worth $223K as of Q1 2026.
Adage Capital Partners bought 844 Acadia Pharmaceuticals shares in Q1 2026, an estimated $20.2K.
Acadia Pharmaceuticals made up ﹤0.01% of Adage Capital Partners's portfolio in Q1 2026, its #911 holding.
Adage Capital Partners first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 8 quarters since.
Adage Capital Partners's Acadia Pharmaceuticals position peaked at $85.1M in Q2 2023.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.